Mitomycin/BCG Combo Shows Similar Efficacy, Reduced BCG Use in NMIBC
A combination of BCG and mitomycin offers a comparable treatment option to BCG monotherapy for NMIBC, potentially lessening the impact of global BCG shortages.
CAN-2409/EBRT Improves Disease-Free Survival in Localized Prostate Cancer
The addition of CAN-2409 to a prodrug and radiation therapy in intermediate-to-high-risk prostate cancer significantly improved cancer-specific outcomes.
Niraparib Plus Abiraterone/Prednisone Extends rPFS in HRR-Altered mCSPC
Niraparib plus abiraterone acetate and prednisone significantly reduced the risk of symptomatic progression in patients with BRCA-mutated metastatic castration-sensitive prostate cancer.
Second-Line Cabozantinib Regimens Exhibit Efficacy in Advanced RCC
Efficacy and safety outcomes in the phase 3 CONTACT-03 study were consistent regardless of patients' prior immunotherapy or tyrosine kinase inhibitor use.
Addition of SBRT to Nivolumab/Ipilimumab Does Not Improve Response in mCRPC
SBRT did not significantly impact response when added to nivolumab/ipilimumab for patients with mCRPC.
Sasanlimab Combo Poised to Change High-Risk NMIBC Treatment Paradigm
Sasanlimab plus BCG significantly improved event-free survival in BCG-naïve, high-risk NMIBC patients, with notable benefit in carcinoma in situ and T1 tumors.
EV-302 Trial Shows ‘Impressive’ Data in Bladder Cancer Responder Population
Approximately 95% of those with a complete response to enfortumab vedotin plus pembrolizumab were alive after 2 years in the phase 3 EV-302 trial.
Frontline Nivolumab Combo Improves TFS Vs Sunitinib in Advanced RCC
Additionally, the 48-month overall survival rate was higher with nivolumab/cabozantinib vs sunitinib in the phase 3 CheckMate 9ER trial.
Delays in All Organ Tumor Progression Observed in Lenvatinib/Pembrolizumab in Advanced RCC
“Our analysis showed that the time to progression was later with the use of lenvatinib and pembrolizumab compared with sunitinib,” said Viktor Grünwald, MD, PhD.
Lenvatinib Combo Improves Clinical Benefit in Clear Cell RCC Subgroups
Additionally, PFS data in the CLEAR trial confirm the benefit of the lenvatinib combination in patients with clear cell RCC regardless of PD-L1 IHC.
HK2-Targeting Radioligand Shows Responses With Some AEs in Metastatic CRPC
Thrombocytopenia and interstitial lung disease following treatment with JNJ-6420 appeared to be manageable with dose schedule modifications.
Pembrolizumab Combo Yields Efficacy in Penile Squamous Cell Carcinoma
Pembrolizumab plus platinum-containing therapy may be a new treatment option for advanced penile cancer based on data from the HERCULES trial.
Novel PROTAC Androgen Receptor Elicits Clinical Activity in Metastatic CRPC
Phase 1/2 data support further development of ARV-766 in advanced prostate cancer, says Daniel P. Petrylak, MD.
EV-302 PRO Outcomes Find Consistent Efficacy Data in Urothelial Carcinoma
Patient-reported outcomes from the EV-302 trial found consistent efficacy and safety outcomes for patients with urothelial carcinoma.
Time to Progression in mHSPC Cohort Prolonged With Darolutamide
The rate of subsequent anticancer therapy was reduced with darolutamide vs placebo in patients with mHSPC in the ARASENS trial.
Circulating KIM-1 May Predict Benefit With Atezolizumab in RCC
KIM-1 was the most significantly enriched circulating protein in recurrence vs baseline serum samples among patients in the IMmotion010 trial.
Extending the Benefits of Avelumab Maintenance in Urothelial Carcinoma
Ongoing research may clarify the potential benefit of avelumab when administered in combination with other agents in advanced urothelial carcinoma.
Predicting Responses to Sacituzumab Govitecan Combo in Urothelial Cancer
Spatial analyses may help determine factors that influence responses to sacituzumab govitecan-containing regimens in urothelial carcinoma.
Enfortumab Vedotin Shows Activity in Cisplatin-Ineligible MIBC
Less than half of the patients enrolled on cohort H of the EV-103 trial required subsequent anticancer therapy following enfortumab vedotin.
Sacituzumab Govitecan Produces Finite Efficacy After Enfortumab Vedotin in Bladder Cancer Subsect
Limited efficacy was observed when sacituzumab govitecan was given after enfortumab vedodin in metastatic urothelial carcinoma.
Pre-Treatment TILs Does Not Impact Nivolumab/Ipilimumab Therapy in mccRCC
Using the TILs CD8-positive, PD-1-positive, TIM3-negative, and LAG3-negative as predictive biomarkers did not impact outcomes in metastatic clear cell renal cell carcinoma.
nmHSPC QOL Remains Consistent After Enzalutamide Schedule Modifications
Data from the EMBARK trial show no significant differences in sexual activity and urinary symptoms when suspending treatment with enzalutamide.
Exploring The Use of Enfortumab Vedotin in Rare Genitourinary Cancers
Attending educational sessions may help with understanding how to manage toxicities associated with enfortumab vedotin in rare genitourinary cancers.
Cabazitaxel/Abiraterone Yields PFS Improvement in mCRPC
CHAARTED2 trial showed an improved progression-free survival in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel, abiraterone acetate, and prednisone.
Sacituzumab Govitecan Yields Response But Questions Remain on Usefulness in Bladder Cancer
Adjuvant sacituzumab govitecan demonstrated a complete response, but its future in bladder cancer is uncertain after a recent protocol amendment.
DFF332 Shows Potential Activity in Advanced Clear Cell RCC
Treatment with DFF332 appears to be safe and tolerable across all dose levels, according to Sumanta Kumar Pal, MD.
Avelumab Plus Chemo Improved Survival in Muscle-Invasive Urothelial Carcinoma
Neoadjuvant avelumab plus cisplatin yielded high event-free survival in muscle-invasive urothelial carcinoma.
Adjuvant Pembrolizumab Shows Statistical Improvement in Survival in ccRCC
Adjuvant pembrolizumab resulted in a reduction in the risk of death in patients with ccRCC.
Four-Year Follow-Up Confirms Lenvatinib/Pembrolizumab Safety in RCC
Common adverse effects following treatment with lenvatinib plus pembrolizumab in the phase 3 CLEAR study include diarrhea, hypertension, and fatigue, according to Thomas E. Hutson, DO, PharmD, FACP.
Lenvatinib Combo Yields Benefit Regardless of IMDC Risk in Advanced RCC
Lenvatinib in combination with pembrolizumab appears to raise no new safety signals in patients with advanced clear cell renal cell carcinoma after 4 years of follow-up in the phase 3 CLEAR study.